| ID Source | ID |
|---|---|
| PubMed CID | 124786 |
| CHEMBL ID | 16779 |
| SCHEMBL ID | 7325845 |
| MeSH ID | M0132237 |
| Synonym |
|---|
| hcbp-gly |
| CHEMBL16779 , |
| (2-benzyl-3-hydroxycarbamoyl-propionylamino)-acetic acid |
| (r,s)(2-benzyl-3-hydroxycarbamoyl-propionylamino)-acetic acid |
| bdbm50002022 |
| (3-(n-hydroxy)carboxamido-2-benzylpropanoyl)glycine |
| SCHEMBL7325845 |
| DTXSID80919328 |
| n-[2-benzyl-1,4-dihydroxy-4-(hydroxyimino)butylidene]glycine |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neprilysin | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0014 | 0.0010 | 0.1702 | 2.3000 | AID67348 |
| Neprilysin | Oryctolagus cuniculus (rabbit) | IC50 (µMol) | 0.0014 | 0.0004 | 0.6611 | 8.2000 | AID147214; AID147516 |
| Neprilysin | Homo sapiens (human) | IC50 (µMol) | 0.0014 | 0.0002 | 0.5422 | 6.7000 | AID147393 |
| Aminopeptidase N | Sus scrofa (pig) | IC50 (µMol) | 0.0020 | 0.0005 | 3.5354 | 8.9000 | AID35686 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| phosphatidylserine binding | Neprilysin | Homo sapiens (human) |
| endopeptidase activity | Neprilysin | Homo sapiens (human) |
| metalloendopeptidase activity | Neprilysin | Homo sapiens (human) |
| protein binding | Neprilysin | Homo sapiens (human) |
| exopeptidase activity | Neprilysin | Homo sapiens (human) |
| zinc ion binding | Neprilysin | Homo sapiens (human) |
| peptide binding | Neprilysin | Homo sapiens (human) |
| protein homodimerization activity | Neprilysin | Homo sapiens (human) |
| oligopeptidase activity | Neprilysin | Homo sapiens (human) |
| cardiolipin binding | Neprilysin | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Neprilysin | Homo sapiens (human) |
| early endosome | Neprilysin | Homo sapiens (human) |
| trans-Golgi network | Neprilysin | Homo sapiens (human) |
| plasma membrane | Neprilysin | Homo sapiens (human) |
| brush border | Neprilysin | Homo sapiens (human) |
| focal adhesion | Neprilysin | Homo sapiens (human) |
| synaptic vesicle | Neprilysin | Homo sapiens (human) |
| cell surface | Neprilysin | Homo sapiens (human) |
| membrane | Neprilysin | Homo sapiens (human) |
| axon | Neprilysin | Homo sapiens (human) |
| dendrite | Neprilysin | Homo sapiens (human) |
| secretory granule membrane | Neprilysin | Homo sapiens (human) |
| cytoplasmic vesicle | Neprilysin | Homo sapiens (human) |
| neuronal cell body | Neprilysin | Homo sapiens (human) |
| neuron projection terminus | Neprilysin | Homo sapiens (human) |
| membrane raft | Neprilysin | Homo sapiens (human) |
| synapse | Neprilysin | Homo sapiens (human) |
| extracellular exosome | Neprilysin | Homo sapiens (human) |
| presynapse | Neprilysin | Homo sapiens (human) |
| plasma membrane | Neprilysin | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID147393 | Inhibitory potency against neutral endopeptidase | 1992 | Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7 | Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. |
| AID35688 | Inhibition of dipeptidyl amino peptidase activity in rat brain with 10 nM [3H]Leu-enkephalin as substrate | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties. |
| AID56053 | Inhibition of [3H]Leu-enkephalin binding to Dipeptidyl aminopeptidase (DAP) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. |
| AID67348 | In vitro inhibition of enkephalinase purified from rat kidney. | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties. |
| AID38366 | Inhibition of Aminopeptidase N activity in pig kidney with 10 nM [3H]Leu-enkephalin as substrate | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties. |
| AID35684 | Inhibition of [3H]Leu-enkephalin binding to aminopeptidase | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. |
| AID35686 | Inhibitory activity against rabbit kidney aminopeptidase using 10 nM of [3H]Leu-enkephalin as substrate | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties. |
| AID147516 | Inhibition of [3H]Ala2-Leu-enkephalin binding to Neutral endopeptidase (NEP) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. |
| AID147214 | Inhibition of neutral endopeptidase activity in rabbit kidney with 20 nM [3H]D-Ala2-Leu-enkephalin as substrate | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties. |
| AID56051 | Inhibitory activity against rat brain Dipeptidyl aminopeptidase using 10 nM of [3H]Leu-enkephalin as substrate | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||